Statistics from Altmetric.com
Only rarely does a new treatment offer a real sea change. An example in the field of neonatology is the use of exogenous surfactant for hyaline membrane disease.1 For the eye, anti-vascular endothelial growth factor (VEGF) drugs may be the therapeutic advance of our time, revolutionising the treatment of vasoproliferative retinopathies including age-related macular degeneration and diabetic retinopathy. In his informative editorial, Sears suggests that anti-VEGF therapy may play a similar role in retinopathy of prematurity.2
Retinopathy of prematurity (ROP) is a vasoproliferative disease, and it is therefore not surprising that there is increasing enthusiasm for anti-VEGF drugs.3 4 …
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.